Page 8 - Corporate Earnings

Reliance Industries: Key financial ratios fall to three-decade low in FY21

On a consolidated basis, firm's RoCE declined to 7.8% in the fiscal

Japan's service prices mark biggest gain in 8 months as Covid pain eases

Japan's corporate services prices rose at the fastest annual pace in eight months in May, data showed

IIFCL profit surges over three-fold to Rs 325 cr in FY21; NPA eases

The gross NPA of the company too declined to 13.9 per cent from 19.70 per cent in the previous financial year.

Jaiprakash Associates posts 86.2% drop in net profit to Rs 424.41 crore

Jaiprakash Associates Ltd (JAL) on Monday reported a decline of 86.2 per cent in its consolidated net profit to Rs 424.41 crore for the fourth quarter ended March 31, 2021. The company had posted a net profit of Rs 3,068.10 crore in the January-March quarter a year ago, JAL said in a BSE filing. However, its revenue from operations was up 34.18 per cent at Rs 2,517.20 crore during the quarter under review as against Rs 1,876.03 crore in the corresponding period last fiscal, the company said. Its total expenses were at Rs 2,212.43 crore, down 4.76 per cent in Q4/FY 2020-21 as against Rs 2,322.95 crore a year ago. For the fiscal year, which ended on March 31, 2021, JAL reported a consolidated net loss of Rs 667.31 crore. It had a net profit of Rs 560.76 crore in the previous year. Its revenue from operations was at Rs 6,405.66 crore in FY 2020-21, down 8.95 per cent. It was Rs 7,035.49 crore in FY 2019-20. Shares of Jaiprakash Associates Ltd on Monday settled at Rs 14.76 apiece, up

Market direction hinges on corporate earnings growth, bond yields

Lockdowns to curtail the lethal second wave of Covid-19 infections have resulted in some earnings downgrade

JB Chemicals & Pharmaceuticals Q4 net profit jumps two-fold to Rs 101 cr

Drug firm JB Chemicals & Pharmaceuticals on Monday reported a two-fold jump in consolidated net profit to Rs 100.81 crore for the quarter ended March 2021 on account of robust sales. The company had posted a net profit of Rs 50.07 crore for the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals said in a regulatory filing. Consolidated revenue from operations stood at Rs 528 crore for the quarter under consideration. It was Rs 444 crore for the same period a year ago, it added. For the full fiscal 2020-21, the net profit of the company was Rs 449 crore as against Rs 272 crore for the previous year, the filing said. Revenue from operations for the fiscal year ended March 2021 stood at Rs 2,043 crore. It was Rs 1,775 crore in FY20. The board of directors has recommended a final dividend of Rs 8 per equity share of face value of Rs 2 for the financial year 2020-21, it added. "Our financial performance for FY21 has been encouraging in one of the most .

TeamLease Services posts consolidated fourth quarter profit of Rs 19.64 cr

Revenue from operations went up marginally by 1 per cent

Prestige Estates Q4 profit jumps multi-folds to Rs 1,336 cr on asset sale

Prestige Estates on Tuesday reported a sharp increase in its consolidated net profit to Rs 1,336.3 crore for the quarter ending March, driven by monetisation of large portfolio of commercial assets.

Top 100 companies' share in cash market turnover drops over the last year

Now below 50%, compared with 75% a year ago

Asian companies witness biggest earnings upgrade in six months

Analysts lifted their forecasts for Asian companies' forward 12-month earnings by 3.9% in May

Seal a tax deal

Minimum global corporate tax rate solves many problems

Our base case projection for Nifty is 17,500 in 12-18 mths: Dhananjay Sinha

We do not think moderation in earnings will have any significant impact on the market. Hence, we see around 15 per cent upside on Nifty

Corporate profit to GDP ratio hits 10-year high of 2.63% in FY21

India Inc's combined net profit was up 57.6% to Rs 5.31 trillion in FY21

Thermax March-quarter net jumps nearly three-fold to Rs 107 crore

Energy solutions firm Thermax said its consolidated net profit jumped nearly three-fold to Rs 107.35 crore for the March quarter, mainly on the back of higher revenues.

AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 cr

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021. The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations of the company stood at Rs 210.25 crore for the quarter under consideration. It was Rs 194.90 crore for the same period a year ago, it added. For the financial year ended March this year, the net profit of the company was Rs 93.30 crore as against Rs 72.22 crore for the previous financial year, the filing said. The company's revenue from operations stood at Rs 813.56 crore for the financial year ended March 31, 2021. It was Rs 831.80 crore for the year-ago fiscal, it added. Shares of AstraZeneca Pharma India closed at Rs 3,862.45 per scrip on BSE, up 0.84 percent from its previous close.

Visible Covid & market rally, invisible growth

The market rally is visible, as is the horrendous impact of Covid 19. What is invisible is earnings growth

Pharma sector's Q4 results show moderate gains amid Covid-19 pandemic

The ongoing April-June quarter should see strong growth due to low base of last year

Analysts cautious on corporate earnings growth amid Covid-led lockdown

During the first wave, FY21 and FY22 Nifty earnings estimates, according to analysts at Jefferies, were cut by 33 per cent and 21 per cent respectively till September 2020

Losing steam

Second wave could derail strong corporate recovery

Best of BS Opinion: Herbs need good marketing, second Covid-19 wave & more

Here are the best of Business Standard's opinion pieces for Monday